Assembly Bioscie Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Assembly Bioscie has an operating margin of -159.3%, meaning the company retains $-159 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -902.5% the prior year.
Assembly Bioscie's revenue surged 298.2% year-over-year to $28.5M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Assembly Bioscie has elevated debt relative to equity (D/E of 2.57), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 16/100, reflecting increased financial risk.
With a current ratio of 2.42, Assembly Bioscie holds $2.42 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.
While Assembly Bioscie generated -$51.1M in operating cash flow, capex of $28K consumed most of it, leaving -$51.1M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Assembly Bioscie passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Assembly Bioscie generates $1.27 in operating cash flow (-$51.1M OCF vs -$40.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Assembly Bioscie (ASMB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Assembly Bioscie generated $28.5M in revenue in fiscal year 2024. This represents an increase of 298.2% from the prior year.
Assembly Bioscie's EBITDA was -$45.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.4% from the prior year.
Assembly Bioscie generated -$51.1M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 327.4% from the prior year.
Assembly Bioscie reported -$40.2M in net income in fiscal year 2024. This represents an increase of 34.4% from the prior year.
Assembly Bioscie earned $-6.69 per diluted share (EPS) in fiscal year 2024. This represents an increase of 50.0% from the prior year.
Assembly Bioscie held $38.3M in cash against $0 in long-term debt as of fiscal year 2024.
Assembly Bioscie had 7M shares outstanding in fiscal year 2024. This represents an increase of 36.0% from the prior year.
Assembly Bioscie's operating margin was -159.3% in fiscal year 2024, reflecting core business profitability. This is up 743.2 percentage points from the prior year.
Assembly Bioscie's net profit margin was -140.9% in fiscal year 2024, showing the share of revenue converted to profit. This is up 713.9 percentage points from the prior year.
Assembly Bioscie invested $55.9M in research and development in fiscal year 2024. This represents an increase of 14.4% from the prior year.
Assembly Bioscie invested $28K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 89.0% from the prior year.
ASMB Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M+12.1% | $9.6M+2.2% | $9.4M+28.0% | $7.4M-13.8% | $8.5M+47.5% | $5.8M-19.2% | $7.2M | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $16.6M+2.9% | $16.1M+8.6% | $14.9M+4.0% | $14.3M-12.2% | $16.3M+36.9% | $11.9M+7.9% | $11.0M+1.7% | $10.8M |
| SG&A Expenses | $5.1M+10.7% | $4.6M+1.9% | $4.5M-2.2% | $4.6M+2.9% | $4.5M-3.4% | $4.6M-46.8% | $8.7M+106.2% | $4.2M |
| Operating Income | -$10.9M+1.9% | -$11.1M-11.6% | -$9.9M+13.8% | -$11.5M+5.5% | -$12.2M-13.7% | -$10.7M+14.5% | -$12.6M+16.6% | -$15.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0 | N/A | $0-100.0% | $406K | N/A | N/A | $0 |
| Net Income | -$9.2M+9.8% | -$10.2M-15.6% | -$8.8M+14.7% | -$10.3M+7.3% | -$11.2M-22.9% | -$9.1M+17.2% | -$11.0M+24.0% | -$14.4M |
| EPS (Diluted) | $-0.72+45.9% | $-1.33-13.7% | $-1.17+24.0% | $-1.54+22.2% | $-1.98-19.3% | $-1.66+5.1% | $-1.75 | $-3.29 |
ASMB Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $240.0M+197.1% | $80.8M-18.4% | $99.0M-16.9% | $119.2M+3.3% | $115.3M-3.8% | $119.9M-12.4% | $136.8M+165.0% | $51.6M |
| Current Assets | $236.8M+205.7% | $77.5M-18.9% | $95.5M-17.3% | $115.5M+2.3% | $112.9M-3.6% | $117.2M-12.4% | $133.8M+169.3% | $49.7M |
| Cash & Equivalents | $22.5M-6.1% | $24.0M+2.5% | $23.4M-38.9% | $38.3M+99.6% | $19.2M+2.4% | $18.7M-5.5% | $19.8M-25.6% | $26.7M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $912K | N/A | N/A | $0 | $0-100.0% | $43K0.0% | $43K | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $57.3M-8.6% | $62.7M-12.8% | $71.9M-16.2% | $85.8M+6.4% | $80.6M-7.6% | $87.3M-8.8% | $95.7M+865.5% | $9.9M |
| Current Liabilities | $53.4M+12.9% | $47.3M+1.4% | $46.6M-2.5% | $47.8M+15.8% | $41.3M+6.5% | $38.8M-1.2% | $39.2M+450.0% | $7.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $182.7M+909.4% | $18.1M-33.3% | $27.1M-18.7% | $33.4M-3.8% | $34.7M+6.4% | $32.6M-20.7% | $41.1M-1.5% | $41.7M |
| Retained Earnings | -$854.1M-1.1% | -$844.9M-1.2% | -$834.7M-1.1% | -$825.9M-2.5% | -$806.0M-1.4% | -$794.8M-1.2% | -$785.7M-1.4% | -$774.8M |
ASMB Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.1M+9.7% | -$16.8M+28.5% | -$23.4M-5659.0% | -$407K+97.6% | -$17.1M+6.9% | -$18.4M-124.9% | $73.6M+631.8% | -$13.8M |
| Capital Expenditures | $42K | $0 | $0 | $0-100.0% | $14K0.0% | $14K-80.3% | $71K-47.8% | $136K |
| Free Cash Flow | -$15.2M+9.4% | -$16.8M+28.5% | -$23.4M-5659.0% | -$407K+97.6% | -$17.1M+6.9% | -$18.4M-125.0% | $73.6M+626.1% | -$14.0M |
| Investing Cash Flow | -$158.3M-1031.3% | $17.0M+158.0% | $6.6M+198.4% | -$6.7M-231.1% | $5.1M-70.4% | $17.3M+119.3% | -$89.7M-574.8% | $18.9M |
| Financing Cash Flow | $171.9M+48060.2% | $357K-81.4% | $1.9M-88.7% | $17.0M+36.5% | $12.5M | $0-100.0% | $9.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ASMB Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -100.9%+14.4pp | -115.2%-9.7pp | -105.5%+51.2pp | -156.8%-13.7pp | -143.0%+42.5pp | -185.5%-10.2pp | -175.2% | N/A |
| Net Margin | -85.2%+20.7pp | -105.9%-12.3pp | -93.6%+46.9pp | -140.5%-9.8pp | -130.7%+26.2pp | -156.9%-3.9pp | -153.0% | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -3.8%+8.8pp | -12.6%-3.7pp | -8.9%-0.2pp | -8.7%+1.0pp | -9.7%-2.1pp | -7.6%+0.4pp | -8.0%+19.9pp | -27.9% |
| Current Ratio | 4.44+2.8 | 1.64-0.4 | 2.05-0.4 | 2.42-0.3 | 2.74-0.3 | 3.02-0.4 | 3.41-3.6 | 6.96 |
| Debt-to-Equity | 0.31-3.1 | 3.46+0.8 | 2.65+0.1 | 2.57+0.2 | 2.33-0.4 | 2.68+0.3 | 2.33+2.1 | 0.24 |
| FCF Margin | -140.7%+33.4pp | -174.1%+74.8pp | -248.9%-243.3pp | -5.5%+195.1pp | -200.6%+117.1pp | -317.7%-1344.8pp | 1027.2% | N/A |
Similar Companies
Frequently Asked Questions
What is Assembly Bioscie's annual revenue?
Assembly Bioscie (ASMB) reported $28.5M in total revenue for fiscal year 2024. This represents a 298.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Assembly Bioscie's revenue growing?
Assembly Bioscie (ASMB) revenue grew by 298.2% year-over-year, from $7.2M to $28.5M in fiscal year 2024.
Is Assembly Bioscie profitable?
No, Assembly Bioscie (ASMB) reported a net income of -$40.2M in fiscal year 2024, with a net profit margin of -140.9%.
What is Assembly Bioscie's earnings per share (EPS)?
Assembly Bioscie (ASMB) reported diluted earnings per share of $-6.69 for fiscal year 2024. This represents a 50.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Assembly Bioscie's EBITDA?
Assembly Bioscie (ASMB) had EBITDA of -$45.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Assembly Bioscie's operating margin?
Assembly Bioscie (ASMB) had an operating margin of -159.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Assembly Bioscie's net profit margin?
Assembly Bioscie (ASMB) had a net profit margin of -140.9% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Assembly Bioscie's free cash flow?
Assembly Bioscie (ASMB) generated -$51.1M in free cash flow during fiscal year 2024. This represents a -327.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Assembly Bioscie's operating cash flow?
Assembly Bioscie (ASMB) generated -$51.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Assembly Bioscie's total assets?
Assembly Bioscie (ASMB) had $119.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Assembly Bioscie's capital expenditures?
Assembly Bioscie (ASMB) invested $28K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Assembly Bioscie spend on research and development?
Assembly Bioscie (ASMB) invested $55.9M in research and development during fiscal year 2024.
How many shares does Assembly Bioscie have outstanding?
Assembly Bioscie (ASMB) had 7M shares outstanding as of fiscal year 2024.
What is Assembly Bioscie's current ratio?
Assembly Bioscie (ASMB) had a current ratio of 2.42 as of fiscal year 2024, which is generally considered healthy.
What is Assembly Bioscie's debt-to-equity ratio?
Assembly Bioscie (ASMB) had a debt-to-equity ratio of 2.57 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Assembly Bioscie's return on assets (ROA)?
Assembly Bioscie (ASMB) had a return on assets of -33.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Assembly Bioscie's cash runway?
Based on fiscal year 2024 data, Assembly Bioscie (ASMB) had $38.3M in cash against an annual operating cash burn of $51.1M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Assembly Bioscie's Piotroski F-Score?
Assembly Bioscie (ASMB) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Assembly Bioscie's earnings high quality?
Assembly Bioscie (ASMB) has an earnings quality ratio of 1.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Assembly Bioscie?
Assembly Bioscie (ASMB) scores 38 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.